opdivo imfinzi growth focu
opdivo/imfinzi upsid keytruda downsid vs street
us io market gross sale mom adj month novemb mrk keytruda
adj shed share in-lin downsid street bmi opdivo
adj lose share in-lin estimate vs street mrk grow
commerci footprint nsclc opdivo diversifi growth key focal pt azn imfinzi gain
share roch tecentriq competit posit improv nsclc approv share
pfe/mrk-et bavencio adj uptak conting rcc dynam
io market nov gross sale mom adj upsid opdivo/imfinzi/tecentriq
symphoni health privat data show us immuno-oncolog io market post gross
sale novemb adjust sell day month-over-month mom merck
buy keytruda bristol-my buy opdivo mom adj respect
astrazeneca azn buy imfinzi grew roch rog-ch rate tecentriq jump surpris
mom hold /merck kgaa mrk-de rate bavencio mom io
market share novemb opdivo keytruda imfinzi tecentriq bavencio
keytruda opdivo lost mom tecentriq imfinzi gain
respect bavencio lost share
keytruda mom adj shed share downsid street
mrk keytruda post us gross sale mom adjust novemb assum
keytruda gross-to-net captur rate captur rate past seven consecut quarter
base keytruda gross sale novemb see us sale estim in-lin
see downsid street estimate conting keytruda sale trajectori dec keytruda
sale novemb impli market share vs octob mrk keytruda establish
foundat io asset investor focus uptak first-lin non-smal cell lung cancer
nsclc market shown overal surviv benefit address patient popul
jan adjuv melanoma feb model keytruda sale vs street
novemb io gross sale data point upsid vs street
estim bmi opdivo azn imfinzi
 roch tecentriq downsid
mrk keytruda depend quarterli captur
rate sale trajectori decemb
opdivo share mom adj growth see upsid street sale
bmi opdivo post us gross sale mom adjust novemb assum opdivo us gross-to-net captur rate base opdivo
us gross sale novemb see upsid street sale in-lin perform estimate conting opdivo
sale trajectori dec note recent see note base manag comment read-out nsclc trial expect
think posit deliv opdivo growth current approv use face rise io competit exampl opdivo
yervoy benefit posit eu chmp opinion enabl domin rcc market eu roll-out assum opdivo share
market see note model opdivo sale in-lin street move estim bmi yervoy mom
adj nov see upsid our/street yervoy net sale base gross sale assum captur
rate conting dec sale trajectori
imfinzi share captur continu penetr stage nsclc market upsid street
azn imfinzi post novemb us gross sale adj mom assum imfinzi us gross-to-net captur rate present
upsid our/street imfinzi us sale estim conting imfinzi sale trajectori dec azn imfinzi distant io
player approv stage nsclc note initi report see note titl oncolog franchis drive margin
expans initi buy rate price think imfinzi stand benefit continu penetr stage nsclc market azn
also numer upcom clinic read-out attract growth opportun imfinzi nsclc azn expect three read-out includ
neptun imfinzi treme nsclc pearl imfinzi nsclc poseidon imfinzi treme chemo nsclc model imfinzi sale
slightli street
tecentriq show bounc share mom adj nsclc approv improv posit
roch tecentriq gross sale novemb mom adj tecentriq saw bounc base tecentriq us gross
sale assumpt see upsid street usd estim conting tecentriq sale trajectori dec view
azn key beneficiari tecentriq share loss expect continu fda approv tecentriq avastin chemo nsq nsclc
three month delay see note also fda action tecentriq abraxan tnbc patient expect march pdufa
date approv tecentriq like first inhibitor launch tnbc along nsclc launch add much-need tecentriq
growth addit roch remain bullish nsclc sclc data present world lung
wclc sept click roch tecentriq approv nsclc appear stabil us io market share
bavencio lose share view bavencio inlyta success io combo rcc
pfe/mrk-d bavencio post us gross sale mom adj asset remain de minimi player io market share
mom note earlier see note titl thought lunch incom ceo head view bavencio inlyta
success io combo regimen show progression-fre surviv benefit treatment-nav renal cell carcinoma rcc howev note
success bavencio inlyta conting bristol-my squibb buy commerci footprint rcc market merck buy keytruda result
studi click note titl bavencio inlyta combo show benefit rcc bavencio fail pivot javelin-
trial third-lin gastric cancer nov recent setback javein trial second-line-plu ovarian cancer studi
note octob novemb sell day respect unless otherwis note month-over-month growth rate adjust sell day
market share calcul adjust
page
exhibit product total gross us monthli sale sep nov
exhibit product gross us sale market share sep nov share
page
exhibit product iqvia im gross us sale mm sep oct
page
page
azn valuat risk
view azn premium valuat price-to-earnings pe basi justifi due differenti oncolog franchis coupl
stabl cvrm ria busi azn trade signific discount peer price/earnings/growth basi suggest
investor skeptic certain key growth opportun rate astrazeneca plc azn buy pt base
ep support dcf analysi
pt also support dcf analysi yield fair valu estim azn base free cash flow estim
termin growth rate weight averag cost capit wacc sensit analysi show
chang termin growth rate wacc assumpt yield chang fair valu respect
oncolog competit pressur could slow growth oncolog key growth driver azn top-lin given bustl activ
therapi area competit pressur risk growth trajectori
cvrm franchis face competit headwind azn partner asset roxadustat could potenti disrupt product ckd
anemia market howev see competit emerg horizon diabet front farxiga byetta/bydureon face intens
competit market-lead jardianc tradjenta respect
clinic risk pipelin could meaning downsid our/street sales/ep estim azn nme/nilex opportun
commerci fall expect
regulatori risk azn unabl secur regulatori approv us eu japan asset could neg impact
abil meet our/street near- long-term project
valuat risk
price assum trade ep premium major biopharmaceut peer group believ
deserv premium base growth prospect substanti premium acquisit bid could command pt support
discount cash flow analysi dcf valu believ compani attract growth dividend yield potenti put
floor bmi stock
risk thesi pt includ clinic regulatori commerci competit risk bmi product failur show overal surviv
os benefit trial nsclc could creat set-back io io opdivo yervoy strategi nsclc wherebi
smaller indic might abl make lost opportun yervoy use could primarili limit melanoma renal cell
carcinoma fail physician concern yervoy toxic profil increas also consid portfolio concentr
out-year invest risk io eliqui account project total revenu
valuat risk
target price assum merck trade ep estim support discount cash flow dcf model
multipl ep group averag think appropri given mrk leadership immuno-oncolog
space keytruda first-mov advantag nsclc
page
risk rate target price includ failur capit truda first-mov advantag nsclc approv use
januvia franchis see materi declin sale due rise competit oral dpp-iv segment clinic
regulatori risk keytruda line extensions/new use multipl early-stag io asset cancer alzheim diseas relebactam
infect herp zoster valent pneumococc vaccin global price risk invest risk relat
biopharmaceut industri includ global price risk payer polit risk clinic develop risk regulatori risk commerci
risk legal risk patent challeng
valuat risk
arriv target price assum stock trade ep believ multipl warrant due
anem growth outlook higher concentr sale gener eh account sale view stock range-
bound sinc manag appear demonstr lack urgenc time pfe dividend yield aggress
share repurchas could add floor stock view dcf analysi yield intrins valu per share
risk rate price target includ increas competit key growth product ibranc xalkori inlyta sutent xtandi
xeljanz bavencio price pressures/high discount rebat demand payer govern greater expect
gener price compress legaci eh product peri-lo addit risk overpay larg biopharma
acquisit convers also note sourc upsid risk could includ earlier expect transform drive sharehold
return better expect perform growth asset instanc eliqui posit blood thin market could add
signific upsid pfe allianc revenu xtandi could receiv boost sale perform non-metastat segment
compani mention note
roch rog-ch rate
merck kgaa mrk-de rate
john bori herebi certifi view express research report accur reflect person view subject
compani secur also certifi receiv direct indirect compens
exchang express specif recommend report
analyst compens base upon stock price perform qualiti analysi commun skill overal revenu profit
firm includ invest bank revenu
page
matter polici practic firm prohibit offer favor research specif research rate specif target price
consider induc receipt busi compens addit associ person prepar research report prohibit
own secur subject compani
rate price target histori astrazeneca plc azn-u
creat bluematrix
rate price target histori bristol-my squibb compani bmy-u
creat bluematrix
page
rate price target histori merck co inc mrk-u
rate price target histori pfizer inc pfe-u
creat bluematrix
creat bluematrix
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report simultan elig client
report avail publish restrict access area websit elig client request password institut
investor corpor member press may also receiv research via third parti vendor includ thomson reuter bloomberg
factset capit iq addit distribut may done sale personnel via email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/librari jsp
pleas email research depart contact strh sale repres
rate system effect oct
strh rate equiti secur
suntrust robinson humphrey strh rate individu equiti use three-tier system stock rate rel broader market
gener next month unless otherwis indic
page
buy stock total return expect outperform relev benchmark next month unless otherwis
hold stock total return expect perform line relev benchmark next month unless
sell stock total return expect under-perform relev benchmark next month unless otherwis
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili suspend due applic regul
and/or strh manag discret previous publish rate target price reli upon
strh analyst price target stock cover unless otherwis indic price target repres analyst expect
stock trade next month unless otherwis indic analyst believ insuffici valuat
driver and/or invest catalyst deriv posit neg invest view may elect approv strh research
manag assign target price likewis certain stock trade may exhibit volatil wherebi assign price target would
unhelp make invest decis research manag approv analyst may refrain assign target
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
total return price appreci dividend price target within period unless otherwis note beta defin
secur averag beta less use bloomberg averag
page
suntrust robinson humphrey rate distribut
